Who
Kristin C. Peck
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Zoetis; Director, BlackRock; Director, BlackRock; Executive Vice President, Pfizer.
In numbers
- Trades disclosed
- 397
- Buys
- 0
- Sells
- 27
- Bought
- $0
- Sold
- $46.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Apr 2010
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $19K720.144 at $26.17 | filing |
| 30 Sep 2026filed 2 Oct 2026 | BLK BlackRockCapital Markets & Asset Management | SEC FORM 4 Code A | —30 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $16K616.089 at $26.22 | filing |
| 10 Jul 2026filed 14 Jul 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $16K616.09 at $26.22 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BLK BlackRockCapital Markets & Asset Management | SEC FORM 4 Code A | —34 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BLK BlackRockCapital Markets & Asset Management | SEC FORM 4 Code A | —34 at $0.00 | filing |
| 10 Apr 2026filed 13 Apr 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $110K2,776.77 at $39.64 | filing |
| 10 Apr 2026filed 13 Apr 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $110K2,776.77 at $39.64 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BLK BlackRockCapital Markets & Asset Management | SEC FORM 4 Code A | —34 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BLK BlackRockCapital Markets & Asset Management | SEC FORM 4 Code A | —34 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $168K4,391.261 at $38.20 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $168K4,391.26 at $38.20 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code M | —7,354 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code F | $461K3,623 at $127.28 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,354.898 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,354.9 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code M | —7,354 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code F | $461K3,623 at $127.28 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —28,072 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —111,060 at $0.00 | filing |
News
ZTS - Zoetis Inc Class A AnalysisZTS · morningstar.com · 12 Oct 2026
0 headlines in the last 90 days name Kristin C. Peck; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.